Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F18%3AE0107121" target="_blank" >RIV/00843989:_____/18:E0107121 - isvavai.cz</a>
Result on the web
<a href="https://ccforum.biomedcentral.com/track/pdf/10.1186/s13054-018-2079-9" target="_blank" >https://ccforum.biomedcentral.com/track/pdf/10.1186/s13054-018-2079-9</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1186/s13054-018-2079-9" target="_blank" >10.1186/s13054-018-2079-9</a>
Alternative languages
Result language
angličtina
Original language name
Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database
Original language description
BACKGROUND: The aim of this study was to describe data on epidemiology, ventilatory management, and outcome of acute respiratory distress syndrome (ARDS) in immunocompromised patients. METHODS: We performed a post hoc analysis on the cohort of immunocompromised patients enrolled in the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE) study. The LUNG SAFE study was an international, prospective study including hypoxemic patients in 459 ICUs from 50 countries across 5 continents. RESULTS: Of 2813 patients with ARDS, 584 (20.8%) were immunocompromised, 38.9% of whom had an unspecified cause. Pneumonia, nonpulmonary sepsis, and noncardiogenic shock were their most common risk factors for ARDS. Hospital mortality was higher in immunocompromised than in immunocompetent patients (52.4% vs 36.2%; p < 0.0001), despite similar severity of ARDS. Decisions regarding limiting life-sustaining measures were significantly more frequent in immunocompromised patients (27.1% vs 18.6%; p < 0.0001). Use of noninvasive ventilation (NIV) as first-line treatment was higher in immunocompromised patients (20.9% vs 15.9%; p = 0.0048), and immunodeficiency remained independently associated with the use of NIV after adjustment for confounders. Forty-eight percent of the patients treated with NIV were intubated, and their mortality was not different from that of the patients invasively ventilated ab initio. CONCLUSIONS: Immunosuppression is frequent in patients with ARDS, and infections are the main risk factors for ARDS in these immunocompromised patients. Their management differs from that of immunocompetent patients, particularly the greater use of NIV as first-line ventilation strategy. Compared with immunocompetent subjects, they have higher mortality regardless of ARDS severity as well as a higher frequency of limitation of life-sustaining measures. Nonetheless, nearly half of these patients survive to hospital discharge.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30221 - Critical care medicine and Emergency medicine
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Critical care
ISSN
1364-8535
e-ISSN
1466-609X
Volume of the periodical
22
Issue of the periodical within the volume
157
Country of publishing house
GB - UNITED KINGDOM
Number of pages
15
Pages from-to
1-15
UT code for WoS article
000435422000002
EID of the result in the Scopus database
2-s2.0-85048497595